Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China
CompanyDeals

Mabwell Bioscience Grants Qilu Pharma Exclusive Rights to Mailisheng in Greater China

Fosun Pharma's Serplulimab Approved for ES-SCLC in the UK and India
CompanyDrug

Fosun Pharma’s Serplulimab Approved for ES-SCLC in the UK and India

Sanofi's Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment
CompanyDrug

Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer
CompanyDrug

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer

AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit
Company

AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit

EMA Panel Recommends Brukinsa Tablet Formulation for Approval
CompanyDrug

EMA Panel Recommends Brukinsa Tablet Formulation for Approval

Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors
CompanyDrug

Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors

CARsgen's Satri-cel NDA Accepted by China's NMPA for Gastric Adenocarcinoma
CompanyDrug

CARsgen’s Satri-cel NDA Accepted by China’s NMPA for Gastric Adenocarcinoma

Lepu Biotech Gains EMA Approval for MRG003 HNSCC Clinical Trial
CompanyDrug

Lepu Biopharma Gains EMA Approval for MRG003 HNSCC Clinical Trial

RemeGen Inks Global Licensing Pact With Vor Bio for Telitacicept
CompanyDeals

RemeGen Inks Global Licensing Pact With Vor Biopharma for Telitacicept

Angel Pharma Gains NMPA Approval for Soquelitinib in Atopic Dermatitis Trial
CompanyDrug

Angel Pharma Gains NMPA Approval for Soquelitinib in Atopic Dermatitis Trial

Biogen's Phase I Results Highlight Salanersen's Potential in Spinal Muscular Atrophy
CompanyDrug

Biogen’s Phase I Results Highlight Salanersen’s Potential in Spinal Muscular Atrophy